



**SUPHA PHARMACHEM LIMITED**  
(Formerly known as Remedium Lifecare Limited)

CIN: L24100MH1988PLC343805 

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,  
Marol, Andheri (East), Mumbai - 400059

info@suphapharmachem.com 

+91 8433895251 

Date: 25/02/2026

To,

**The Secretary**  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai 400 001

**Company Code No.: 539561**

Dear Sir,

**Sub.: Intimation of further Postponement and Rescheduling of Board Meeting under Regulation 29 of SEBI (LODR) Regulations, 2015**

**Ref: To consider Un-Audited Financial Results/Statements (Standalone & Consolidated) of the Company for the Third Quarter and Nine months ended December, 31, 2025 and update on Trading Window**

Further to our letter dated 3<sup>rd</sup> February, 2026 read with letter dated 14<sup>th</sup> February, 2026, we hereby inform you that the meeting of the Board of Directors of the Company re-scheduled to be held on Wednesday, February 25, 2026 (originally scheduled on 14<sup>th</sup> February, 2026) has been now further postponed due to non-availability of financial information of the overseas subsidiary (Singapore), which is required for finalisation of the consolidated financial results. The said Board Meeting has now been rescheduled to be held on **Monday, 9<sup>th</sup> March, 2026** to consider the below matters:

1. To consider and approve unaudited Standalone Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2025.
2. To consider and approve unaudited Consolidated Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2025.

We hereby further inform you that as the Unaudited standalone and consolidated results not available for consideration and approval due to non-availability of financial information of the overseas subsidiary (Singapore), which is required for finalisation of the consolidated financial results.

Kindly consider this as an intimation in terms of the provisions of Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, **as amended and take the same on your records.**

Further, the trading window, which was earlier intimated in connection with the said Board Meeting pursuant to Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading



**SUPHA PHARMACHEM LIMITED**

*(Formerly known as Remedium Lifecare Limited)*

CIN: L24100MH1988PLC343805 

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,  
Marol, Andheri (East), Mumbai - 400059

info@suphapharmachem.com 

+91 8433895251 

by Insiders, the Trading Window for dealing in the securities of the Company for the Insiders and all the designated persons as defined in the code is closed from 1<sup>st</sup> January, 2026 and will re-open after 48 hours of declaration of Un-Audited Financial results/statements (Standalone & Consolidated) for the Third Quarter and Nine months ended December, 31, 2025.

The above is for your information and dissemination to all the stakeholders.

Yours faithfully,

Thanking you,

**For SUPHA PHARMACHEM LIMITED**  
**(Formerly known as Remedium Lifecare Limited)**



**Adarsh Munjal**  
**Whole Time Director**  
**DIN.: 07304004**